Investor decision tool

Weighted checklist with scoring breakdown. Answer criteria, then export an IC memo (.md) or follow workflow links to manufacturing, claims, and company comparables.

Export & workflow

Select yes / partial / no / unknown on at least one criterion below to enable export.

Defined source cell, MCB/WCB, controlled production stateDeal breaker

Traceable cell identity and banking per GMP expectations.

2017Gimona
Weight 20%

Mechanism-linked potency assayDeal breaker

Potency linked to MOA—not decorative surrogate panels alone.

2017Willis2024ISEV
Weight 25%

Scalable closed manufacturing process

Defined isolation, comparability plan, and release testing.

2022Ahn
Weight 20%

Indication with plausible EV delivery advantage

Local/targeted or differentiated delivery vs standard modalities.

2024Aegle2017Gimona
Weight 20%

No clinic-economics or vague 361 positioningDeal breaker

Therapeutic claims require IND/GMP path; avoid unapproved clinic models.

2020U.S.2019U.S.
Weight 15%

Scoring output

25%

Do not proceed without resolving deal-breaker gaps. Expert validation recommended on CMC and potency claims.

  • Defined source cell, MCB/WCB, controlled production state
  • Mechanism-linked potency assay
  • No clinic-economics or vague 361 positioning
CriterionAnswerWeighted
Defined source cell, MCB/WCB, controlled production stateunknown5.0 / 20
Mechanism-linked potency assayunknown6.3 / 25
Scalable closed manufacturing processunknown5.0 / 20
Indication with plausible EV delivery advantageunknown5.0 / 20
No clinic-economics or vague 361 positioningunknown3.8 / 15